Claims 106 and 115 have been amended by additionally indicating that the transformed cells can be syngeneic cells as well as cells "originating from the mammal." Support for this amendment may be found at page 33, lines 1-4, of the specification.

Claim 120 has been amended by replacing the phrase "has a diagnostic effect" with the phrase "is a gene product of a marker gene." Support for this amendment may be found at page 30, lines 10-26 and at page 31, lines 1-7, of the specification.

These amendments are made solely to clarify Applicants' invention and are not related to patentability.

Claims 106-142 are pending in the present application. Applicants now submit that the claims are ready for examination on the merits and respectfully request examination thereof.

Respectfully Submitted,

C. Noel Kaman

Reg. No. 51,857 Attorney for Applicant

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312)321-4200

## Appendix A – Version with Markings to Show Changes Made to the Claims

(h)

- 106. (Twice Amended) A method of introducing protein in a mammal which comprises delivering to a blood vessel in the mammal a [transfected] transformed vascular cell, the [transfected] transformed cell originating from the mammal or being syngeneic to the mammal and comprising an exogenous nucleic acid encoding the protein and competent to express the protein when implanted in the mammal.
- 107. (Amended) The method of claim 106 wherein the [transfected] <u>transformed</u> cell becomes attached to the wall of the vessel in the mammal.
- 108. (Amended) The method of claim 106 wherein the [transfected] <u>transformed</u> cell is an endothelial cell or a smooth muscle cell.
- 115. (Twice Amended) A method of treating a human patient comprising the step of site-specific instillation of cells into the patient, wherein the cells originate from the patient or are syngeneic to the patient and are selected from the group consisting of endothelium, smooth muscle, and parenchymal cells.
- 120. (Amended) The method of claim 116, wherein the protein [has a diagnostic effect] is a gene product of a marker gene.